NexaVant™ - TLR3 Agonist

TLR3 agonist - NexaVant™ (NVT)

NexaVant™ is a double-stranded (ds) RNA-based TLR3 agonist and promising vaccine adjuvant. NexaVant™ (NVT) is a synthetic dsRNA of 424 bp produced by performing PCR-coupled bidirectional in vitro transcription of a viral nucleotide segment using T7 RNA polymerase technology.

NexaVant™ displays high purity (≥ 95%) and molecular homogeneity, therefore overcoming various obstacles of currently available dsRNA-based adjuvant candidates, including Poly(I:C) [1]. It induces NF-κB and IRF responses in HEK-Dual™ hTLR3 cells stronger than Poly(A:U), although it is less potent than Poly(I:C) HMW (see figures). Moreover, it does not trigger serious toxicity in preclinical studies [1]. Notably, NexaVant™ has shown promise as an adjuvant for T cell vaccines, enhancing Th1 immune responses and promoting lung-resident memory T cells for long-term and broad protection against respiratory pathogens [2-3].

InvivoGen also offers NexaVant™ VacciGrade™, a high-quality pre-clinical grade suited for in vivo studies.

Key features

• Potent TLR3 agonist and vaccine adjuvant
• Highly pure (≥ 95%) and stable
• Ready-to-use liquid
• Batch-to-batch consistency
• Each lot is functionally tested

References:

1. Ko KH, et al., 2023. A novel defined TLR3 agonist as an effective vaccine adjuvant. Front Immunol. ;14:1075291.
2. Ko KH, et al. 2024. A vaccine platform targeting lung-resident memory CD4+ T-cells provides protection against heterosubtypic influenza infections in mice and ferrets. Nat Commun.15(1):10368.
3. Ko KH, et al. 2025. A vaccine targeting lung resident-memory CD4(+) T cell phenotype protects against Mycobacterium tuberculosis in mice. NPJ Vaccines. 10(1):161.